Table 1 Patient characteristics before baseline PSMA-PET/CT.

From: Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic/oligoprogressive castration resistant prostate cancer

 

Radiotherapy group MW + (Range)

Control group MW + (Range)

Initial tumor presentation

Initial PSA-Value (ng/ml)

47.5 (2.7–508)

73.52 (2.0–443.0)

Initial Gleason (prostate biopsy)

8.03 (6–9)

8.37 (7–10)

Risk group

Low risk

Intermediate risk

High risk

n = 1 (2.94%)

n = 3 (8.82%)

n = 20 (58.82%)

n = 1 (5.26%)

n = 3 (15.79%)

n = 8 (42.11%)

N + 

M + 

n = 8 (23.53%)

n = 2 (5.88%)

n = 4 (21.05%)

n = 3 (15.79%)

UICC stage I

UICC stage II

n = 6 (17.65%)

n = 3 (8.82%)

n = 2 (10.53%)

n = 3 (15.79%)

UICC stage III

UICC stage IV

n = 14 (41.18%)

n = 11 (32.35%)

n = 6 (31.58%)

n = 8 (42.11%)

Charlson Morbidity Index (CCI)

0 Point

n = 27 (79.41%)

n = 15 (71.43%)

CCI 1 point

CCI 2 points

n = 5 (14.71%)

n = 1 (4.76%)

n = 5 (23.81)

n = 0

Primary therapy

RPE

n = 24 (64.71%)

n = 13 (61.90%)

Primary radiotherapy

n = 6 (17.64%)

n = 2 (9.52%)

Salvage radiotherapy

n = 18 (52.94%)

n = 8 (38.10%)

Primary ADT only

n = 4 (11.76%)

n = 6 (28.57%)

other (RFA/ HIFU etc.)

n = 1 (2.94%)

 

Therapy before PSMA-PET/CT

Bicalutamid/LHRH

n = 34 (100%)

n = 21 (100%)

ARPI before PSMA-PET/CT

n = 1 (2.94%)

n = 0

Cytostatic therapy before PSMA-PET/CT

n = 1 (2.94%)

n = 0

Additional subsequent local therapy before PSMA-PET/CT not confined to prostate (e.g. radiotherapy and/or surgery for bone metastatses)

n = 6 (17.64%)

n = 2 (9.52%)

Patient characteristics before PSMA-PET

Age at PSMA-PET (years)

71.05 (50–84)

73.28 (65–85)

Time from initial diagnosis to PSMA-PET (months)

82.29 (14–197)

100.14 (9–257)

PSA level at the time of PSMA-PET

7.10 (0.38–100) ng/ml

7.85 (0.04–46.0) ng/ml

PSA doubling time at the time of PSMA-PET

5.29 (0.87–23.7) months

5.52 (1.95–19.6) months

Duration of ADT intake until PSMA-PET

60.32 (6–197) months

56.09 (6–149) months

PSMA-PET findings

Untreated/relapsed primary tumor

n = 7

n = 11

Pelvic lymphnodes (N)

n = 25 (10 patients)

n = 17 (9 patients)

Extrapelvic lymphnodes (M1a)

n = 19 (12 patients)

n = 18 (7 patients)

Bone metastases (M1b)

n = 30 (16 patients)

n = 7 (6 patients)

Number of PSMA avid lesions per patient

2.4

2.5

Back to article page